Complications of a trophic xenotransplant approach in parkinsonian monkeys
Identifieur interne : 000261 ( PascalFrancis/Curation ); précédent : 000260; suivant : 000262Complications of a trophic xenotransplant approach in parkinsonian monkeys
Auteurs : Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis]Source :
- Progress in neuro-psychopharmacology & biological psychiatry [ 0278-5846 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- Animal, Biological activity, Brain (vertebrata), Cell, Central nervous system, Chemotherapy, Complication, Corpus striatum, Encapsulation, Gene therapy, Glial cell line derived neurotrophic factor, Implant, Long term, Monkey, Parkinson disease, Toxicity, Transplantation, Treatment, Treatment efficiency.
Abstract
Various restorative cell transplantation strategies have been investigated to substitute for lost dopamine (DA) neurons or to enhance DA synthesis in Parkinson's disease. Intracerebral implantation of engineered cells encapsulated in a semipermeable polymer membrane constitutes one way to deliver bioactive substances unable to cross the blood-brain barrier while avoiding the need for long-term immunosuppression. Glial cell line-derived neurotrophic factor (GDNF) has shown trophic effects on DA neurons but effective and sustained delivery within the brain parenchyma remains problematic. The long-term efficacy and late complications of a xenotransplant approach utilizing GDNF-expressing encapsulated baby hamster kidney (BHK) cells were examined. Each of five MPTP-lesioned parkinsonian cynomolgus monkeys received five devices containing active or inert cells grafted bilaterally in the striatum in a two-stage procedure 9 months apart and animals were sacrificed 4 months later for analyses. No definite motor benefit was observed, DA levels were comparable between GDNF- and control cell-implanted striata, and tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra showed no consistent recovery. Cell viability and GDNF synthesis in the explanted devices were negligible. The brain tissue surrounding all implants showed an intense immune reaction with prominent "foreign body" inflammatory infiltrates. Membrane biophysics, the cell type used, and the extended period of time the devices remained in situ may have contributed to the negative outcome and should be addressed in future investigations using this approach.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A62
Links to Exploration step
Pascal:03-0390767Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Complications of a trophic xenotransplant approach in parkinsonian monkeys</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Stomatology, Faculty of Dental Medicine, University of Montreal and Neuroscience Research Unit, CHUM</s1>
<s2>Montreal, PQ</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Konitsiotis, Spiros" sort="Konitsiotis, Spiros" uniqKey="Konitsiotis S" first="Spiros" last="Konitsiotis">Spiros Konitsiotis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, University of Ioannina Medical School</s1>
<s2>Ioannina</s2>
<s3>GRC</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Pluta, Ryszard" sort="Pluta, Ryszard" uniqKey="Pluta R" first="Ryszard" last="Pluta">Ryszard Pluta</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F." last="Emerich">Dwaine F. Emerich</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Cyto Therapeutics Inc.</s1>
<s2>Providence, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Sertoli Technologies Inc.</s1>
<s2>Cranston, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0390767</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0390767 INIST</idno>
<idno type="RBID">Pascal:03-0390767</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A62</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000261</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Complications of a trophic xenotransplant approach in parkinsonian monkeys</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Stomatology, Faculty of Dental Medicine, University of Montreal and Neuroscience Research Unit, CHUM</s1>
<s2>Montreal, PQ</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Konitsiotis, Spiros" sort="Konitsiotis, Spiros" uniqKey="Konitsiotis S" first="Spiros" last="Konitsiotis">Spiros Konitsiotis</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, University of Ioannina Medical School</s1>
<s2>Ioannina</s2>
<s3>GRC</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Mochizuki, Hideki" sort="Mochizuki, Hideki" uniqKey="Mochizuki H" first="Hideki" last="Mochizuki">Hideki Mochizuki</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Pluta, Ryszard" sort="Pluta, Ryszard" uniqKey="Pluta R" first="Ryszard" last="Pluta">Ryszard Pluta</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Emerich, Dwaine F" sort="Emerich, Dwaine F" uniqKey="Emerich D" first="Dwaine F." last="Emerich">Dwaine F. Emerich</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Cyto Therapeutics Inc.</s1>
<s2>Providence, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Sertoli Technologies Inc.</s1>
<s2>Cranston, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Progress in neuro-psychopharmacology & biological psychiatry</title>
<title level="j" type="abbreviated">Prog. neuro-psychopharmacol. biol. psychiatr.</title>
<idno type="ISSN">0278-5846</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Progress in neuro-psychopharmacology & biological psychiatry</title>
<title level="j" type="abbreviated">Prog. neuro-psychopharmacol. biol. psychiatr.</title>
<idno type="ISSN">0278-5846</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Biological activity</term>
<term>Brain (vertebrata)</term>
<term>Cell</term>
<term>Central nervous system</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Corpus striatum</term>
<term>Encapsulation</term>
<term>Gene therapy</term>
<term>Glial cell line derived neurotrophic factor</term>
<term>Implant</term>
<term>Long term</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Toxicity</term>
<term>Transplantation</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Facteur GDNF</term>
<term>Transplantation</term>
<term>Cellule</term>
<term>Encapsulation</term>
<term>Thérapie génique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Implant</term>
<term>Efficacité traitement</term>
<term>Complication</term>
<term>Toxicité</term>
<term>Animal</term>
<term>Singe</term>
<term>Corps strié</term>
<term>Activité biologique</term>
<term>Encéphale</term>
<term>Système nerveux central</term>
<term>Long terme</term>
<term>Lignée BHK</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Various restorative cell transplantation strategies have been investigated to substitute for lost dopamine (DA) neurons or to enhance DA synthesis in Parkinson's disease. Intracerebral implantation of engineered cells encapsulated in a semipermeable polymer membrane constitutes one way to deliver bioactive substances unable to cross the blood-brain barrier while avoiding the need for long-term immunosuppression. Glial cell line-derived neurotrophic factor (GDNF) has shown trophic effects on DA neurons but effective and sustained delivery within the brain parenchyma remains problematic. The long-term efficacy and late complications of a xenotransplant approach utilizing GDNF-expressing encapsulated baby hamster kidney (BHK) cells were examined. Each of five MPTP-lesioned parkinsonian cynomolgus monkeys received five devices containing active or inert cells grafted bilaterally in the striatum in a two-stage procedure 9 months apart and animals were sacrificed 4 months later for analyses. No definite motor benefit was observed, DA levels were comparable between GDNF- and control cell-implanted striata, and tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra showed no consistent recovery. Cell viability and GDNF synthesis in the explanted devices were negligible. The brain tissue surrounding all implants showed an intense immune reaction with prominent "foreign body" inflammatory infiltrates. Membrane biophysics, the cell type used, and the extended period of time the devices remained in situ may have contributed to the negative outcome and should be addressed in future investigations using this approach.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0278-5846</s0>
</fA01>
<fA02 i1="01"><s0>PNPPD7</s0>
</fA02>
<fA03 i2="1"><s0>Prog. neuro-psychopharmacol. biol. psychiatr.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Complications of a trophic xenotransplant approach in parkinsonian monkeys</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BLANCHET (Pierre J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KONITSIOTIS (Spiros)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MOCHIZUKI (Hideki)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PLUTA (Ryszard)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>EMERICH (Dwaine F.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHASE (Thomas N.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MOURADIAN (M. Maral)</s1>
</fA11>
<fA14 i1="01"><s1>Experimental Therapeutics Broach, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Stomatology, Faculty of Dental Medicine, University of Montreal and Neuroscience Research Unit, CHUM</s1>
<s2>Montreal, PQ</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, University of Ioannina Medical School</s1>
<s2>Ioannina</s2>
<s3>GRC</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Cyto Therapeutics Inc.</s1>
<s2>Providence, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Sertoli Technologies Inc.</s1>
<s2>Cranston, RI</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>607-612</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17544</s2>
<s5>354000119853230070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0390767</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Progress in neuro-psychopharmacology & biological psychiatry</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Various restorative cell transplantation strategies have been investigated to substitute for lost dopamine (DA) neurons or to enhance DA synthesis in Parkinson's disease. Intracerebral implantation of engineered cells encapsulated in a semipermeable polymer membrane constitutes one way to deliver bioactive substances unable to cross the blood-brain barrier while avoiding the need for long-term immunosuppression. Glial cell line-derived neurotrophic factor (GDNF) has shown trophic effects on DA neurons but effective and sustained delivery within the brain parenchyma remains problematic. The long-term efficacy and late complications of a xenotransplant approach utilizing GDNF-expressing encapsulated baby hamster kidney (BHK) cells were examined. Each of five MPTP-lesioned parkinsonian cynomolgus monkeys received five devices containing active or inert cells grafted bilaterally in the striatum in a two-stage procedure 9 months apart and animals were sacrificed 4 months later for analyses. No definite motor benefit was observed, DA levels were comparable between GDNF- and control cell-implanted striata, and tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra showed no consistent recovery. Cell viability and GDNF synthesis in the explanted devices were negligible. The brain tissue surrounding all implants showed an intense immune reaction with prominent "foreign body" inflammatory infiltrates. Membrane biophysics, the cell type used, and the extended period of time the devices remained in situ may have contributed to the negative outcome and should be addressed in future investigations using this approach.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur GDNF</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Glial cell line derived neurotrophic factor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor GDNF</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Transplantation</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Transplantation</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trasplantación</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cellule</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cell</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Célula</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Encapsulation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Encapsulation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Encapsulación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Thérapie génique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Gene therapy</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Terapia génica</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Implant</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Implant</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Implante</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Complication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Complication</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Complicación</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Animal</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Animal</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Animal</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Singe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Monkey</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Mono</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Corps strié</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Corpus striatum</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>33</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>34</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>34</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>34</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Long terme</s0>
<s5>78</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Long term</s0>
<s5>78</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>78</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Lignée BHK</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Surgery</s0>
<s5>53</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>53</s5>
</fC07>
<fN21><s1>272</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000261 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000261 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:03-0390767 |texte= Complications of a trophic xenotransplant approach in parkinsonian monkeys }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |